Repeated-Dose Toxicity: Scientifically Uncovering the Hidden Risks of Long-Term Exposure

In the safety assessment of chemicals, acute toxicity tests represent only the first step. In real life, people and the environment are generally not exposed to substances just once; rather, they are exposed to repeated doses over the course of days, weeks, or months. Repeated-dose toxicity is a comprehensive set of toxicological studies that evaluates the systemic toxic effects resulting from the daily administration of a test substance over a specific period. These tests directly inform the determination of safe exposure limits for human health by revealing a substance’s cumulative effects, adaptation mechanisms, target organ damage, and delayed toxic responses. Our laboratory conducts repeated-dose toxicity studies in accordance with current OECD guidelines, under GLP principles, and with full adherence to the 3R approach.

The Scientific Basis and Importance of Repeated-Dose Toxicity

Acute toxicity tests demonstrate the effects that a single high dose of a substance can cause. However, this approach cannot detect the damage that long-term exposure to low doses may cause. Some substances can accumulate in the body and, over time, exceed the toxic threshold; others may cause small but irreversible damage with each administration, thereby paving the way for chronic diseases. Repeated-dose toxicity studies are specifically designed to uncover these hidden risks.

The most critical outcome of these studies is the determination of the NOAEL (No Observed Adverse Effect Level)—that is, the highest dose level at which no observable adverse effects are detected. The NOAEL value serves as the fundamental parameter for calculating safe exposure limits for humans. Values such as the Acceptable Daily Intake (ADI), Tolerable Daily Intake (TDI), and Occupational Exposure Limits (OEL) are derived by dividing the NOAEL by uncertainty factors. In addition, the LOAEL (Lowest Observed Adverse Effect Level)—that is, the lowest dose level at which an adverse effect is observed—is also used in risk assessment, particularly when the NOAEL cannot be determined.

Repeated-dose studies also allow for the characterization of target organ toxicity. Critical information—such as which organs a substance affects, the dose-response relationship of these effects, whether they are reversible, and gender-based differences—is derived from the results of these studies. This information enables a comprehensive understanding of the substance’s potential risks to human health and is directly used in the decision-making processes of regulatory authorities.

OECD Guidelines: The Evaluation Process Ranging from 28 to 90 Days

In repeated-dose toxicity assessments, different OECD guidelines are used depending on the duration and scope of the study.
OECD TG 407 is a 28-day repeated-dose oral toxicity test and is typically conducted as an initial screening study. This test is used to identify a chemical’s target organs, understand the dose-response relationship, and select an appropriate dose range for longer-term studies. The test substance is administered orally to test animals daily for 28 days; at least three dose levels and a control group are used. Observation parameters include clinical signs, body weight, feed and water intake, hematological and clinical biochemistry analyses, organ weights, and detailed histopathological examinations.

OECD TG 408 is a 90-day subchronic oral toxicity test and offers a longer exposure period and more comprehensive assessment parameters compared to TG 407. The 90-day administration period allows for the emergence of the substance’s cumulative effects, adaptation mechanisms, and delayed toxic responses. In this study, parameters such as hematology, clinical biochemistry, and urinalysis are examined across a broader panel; the histopathological evaluation covers more organs than in TG 407. TG 408 is a mandatory data requirement under the EU REACH regulation for substances produced in quantities exceeding 100 metric tons per year.

The choice between these two guidelines depends on the substance’s production volume, usage scenario, and regulatory requirements. While TG 407 is used for early screening and dose determination, TG 408 is preferred when a more comprehensive safety assessment is required. Our laboratory conducts both tests in full and recommends the most appropriate strategy to our clients. The table below provides a comparative summary of the key features of these two guidelines.

The Role of Clinical Pathology and Histopathological Evaluation

One of the most valuable components of repeated-dose toxicity studies is a comprehensive clinical pathology evaluation. Hematology analyses include parameters such as red blood cell count, hemoglobin concentration, hematocrit, white blood cell count, and platelet count. Changes in these values may indicate conditions such as anemia, infection, bone marrow suppression, or immune system involvement. Clinical biochemistry analyses, on the other hand, cover parameters such as liver enzymes (ALT, AST, ALP), kidney function markers (creatinine, urea), electrolytes, protein levels, and lipid profile. Abnormalities in these values may reveal early signs of target organ toxicity.

Histopathological evaluation forms the backbone of repeated-dose studies. In this examination, conducted by certified veterinary pathologists, every organ and tissue is systematically evaluated under a microscope. Findings such as cellular degeneration, necrosis, inflammation, fibrosis, hypertrophy, hyperplasia, and neoplastic changes are characterized within a dose-response relationship. Evaluation using a blinded method ensures the objectivity of the results. In our laboratory, histopathological evaluations are performed using the internationally recognized INHAND terminology, and all findings are reported in detail.

The integrated interpretation of clinical pathology and histopathology data enables a comprehensive understanding of the substance’s toxicological profile. For example, an elevation in liver enzymes observed in clinical biochemistry, combined with the detection of centrilobular necrosis in the liver via histopathology, constitutes definitive evidence of hepatotoxicity. This integrated approach helps prevent false-positive or false-negative results and builds confidence among regulatory authorities.

Critical Elements of Dose Selection and Study Design

The success of repeated-dose toxicity studies depends on proper dose selection.
Very high doses can cause severe toxicity that does not reflect the substance’s actual conditions of use and may make it difficult to use the results in human health assessments. Very low doses, on the other hand, may fail to reveal the substance’s toxic potential and create a false sense of safety. Therefore, dose selection is carried out meticulously based on available acute toxicity data, structure-activity relationship analyses, and preliminary dose-finding studies. The maximum tolerated dose (MTD) approach involves selecting the highest dose that will produce noticeable toxicity but will not cause death or extreme pain.

The route of administration should correspond to the expected route of human exposure to the test substance. For oral administration, methods such as gavage, mixing with diet, or addition to drinking water may be used. Gavage ensures accurate dose control, while administration via diet or drinking water simulates more natural exposure conditions. The choice depends on factors such as the test substance’s stability, solubility, and taste. Our laboratory ensures accurate and consistent exposure by validating the stability and homogeneity of the test substance in the administration matrix prior to each study.

Observation frequency and parameters are critical to the scientific validity of the study. Clinical signs are monitored daily, while body weight and feed intake are monitored weekly. Clinical pathology evaluations are performed at the beginning and end of the study; interim evaluations may also be included in 90-day studies. All observations are conducted according to a scheduled timeline in accordance with GLP-compliant standard operating procedures. This systematic approach ensures that the data are complete and comparable.

Conducting Repeated-Dose Toxicity Studies in Our Laboratory

In our GLP-certified laboratory, repeated-dose toxicity studies are conducted through a systematic process that is fully compliant with international standards. The process begins with a comprehensive preliminary evaluation. The study protocol is designed by taking into account the test substance’s physicochemical properties, existing toxicity data, chemical structure, and the expected human exposure scenario. Dose levels are determined based on scientific justification and approved by the study director.

During the administration phase, the test substance is administered via the specified route and at the specified frequency. In gavage administrations, each animal receives a dose calculated based on body weight; in diet or drinking water administrations, the stability and homogeneity of the test substance are regularly verified. To verify exposure levels, toxicokinetic analyses are performed as needed; systemic exposure is demonstrated by measuring plasma or tissue concentrations. This approach strengthens the extrapolation of results to human risk assessment.

Throughout the study, the clinical status of the animals is assessed daily. Body weight and feed intake are measured weekly. Additional examinations, such as ophthalmological examinations, neurobehavioral assessments, and urinalysis, may be included depending on the scope of the study. At the end of the study, necropsies are performed on all animals; organ weights are measured, and tissue samples are collected for histopathological examination. Histopathological evaluation, conducted by certified veterinary pathologists, is performed using a blinded method and INHAND terminology.

One of our laboratory’s key advantages is the integration of toxicokinetic data into the study design. Toxicokinetic analyses performed on satellite groups enable the determination of parameters such as Cmax (maximum plasma concentration), AUC (area under the curve), and half-life. These data make it possible to verify systemic exposure and interpret the dose-response relationship more accurately. The integration of toxicokinetic data is becoming increasingly important in modern risk assessment approaches, and our laboratory has the infrastructure to meet this requirement.

Frequently Asked Questions

One of the most common questions we encounter regarding repeated-dose toxicity studies is whether it is possible to move directly from a 28-day study to a 90-day study. Although theoretically possible, selecting a dose for a chronic study without knowing the subchronic NOAEL carries a high risk. Therefore, a stepwise approach is generally recommended: first, target organs and the toxicity range are identified using TG 407, followed by a more comprehensive evaluation using TG 408. This approach both enhances scientific validity and prevents unnecessary animal use.

Another common question is what to do when a NOAEL cannot be determined. If an adverse effect is observed even at the lowest dose, a LOAEL is determined, and a risk assessment is performed using uncertainty factors. If necessary, an additional study with lower doses can be designed. There is also interest in which regulatory formats test results can be presented in. A complete study report compliant with OECD templates can be submitted in IUCLID format or in the specific format required by the regulatory authority.

Whether the integration of toxicokinetic data is mandatory is also frequently asked. Although not mandatory in OECD guidelines, it is strongly recommended in modern risk assessment approaches to verify systemic exposure and facilitate extrapolation to humans. Our laboratory integrates toxicokinetic analyses into the study design, ensuring that the results carry greater weight with regulatory authorities. Finally, there are questions regarding how detailed histopathology reports should be. The incidence, severity, distribution, and dose-response relationship for each lesion should be reported; the biological significance of the findings should be interpreted by the pathologist.

Repeated-dose toxicity provides scientific evidence of a chemical’s long-term safety profile. The proper design and meticulous execution of these studies directly impact the speed and success of your product’s regulatory approval process. Our laboratory conducts repeated-dose toxicity studies in accordance with current OECD guidelines, in full adherence to the 3R principles, and in compliance with GLP standards. With our experienced team of toxicologists and certified veterinary pathologists, contact us to collaboratively plan the most appropriate testing strategy for your product.